Ralph Lauren Corp vs Revvity Inc — how do they compare? Ralph Lauren Corp trades at $368.24 (market cap $21.89B), while Revvity Inc trades at $153.89 (market cap $16.98B). The key difference: Ralph Lauren Corp is the larger of the two by market cap, and Ralph Lauren Corp pays the higher dividend (1.09%). Which is the better fit depends on your goals — on Pluang, investors hold Ralph Lauren Corp for 84 Days and Revvity Inc for 12 Days on average.
| RL | RVTY | |
|---|---|---|
Market Cap | $21.89B | $16.98B |
Volume | 481,617 | 1,456,900 |
Sector | Consumer Cyclical | Health |
52-Week High | $414.25 | $157.36 |
52-Week Low | $309.29 | $82.26 |
Typical Hold Time | 84 Days | 12 Days |
Enterprise Value | $22.95B | $19.30B |
Dividend Yield | 1.09% | 0.18% |
Signals from Pluang's Aura AI — not financial advice
Ralph Lauren (RL) trades at $361.14, down 2.04% on the day, amid a bearish technical signal but strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue and net income have grown steadily, reaching $7.08 billion and $743 million in 2025, respectively, while profitability metrics like a 70.27% gross margin and 37.54% ROE highlight operational strength. Analyst sentiment remains bullish with a consensus price target of $456.67, though technical indicators show near-term resistance at $363.
The outlook for RL is positive based on fundamental growth and analyst support, but investors face risks from market volatility and execution challenges. The stock's current valuation at a P/E of 23.15 appears reasonable given earnings momentum, yet competitive pressures and macroeconomic factors could limit upside. Institutional confidence is high, with 66.67% of analysts rating it a buy, suggesting potential for appreciation if the company maintains its earnings trajectory.
RVTY trades at $153.60, up 0.2% today and near its 52-week high of $158.28 (Defense World, 2026-10-01). The stock shows a bullish technical trend with strong moving average signals and has beaten earnings estimates for three consecutive quarters. Recent developments include the launch of a CE-IVDR-certified T1D screening kit in Europe (Business Wire, 2026-09-24) and the acquisition of Human Cell Design to expand metabolic disease research tools (Business Wire, 2026-09-09).
The outlook is positive, supported by earnings momentum, strategic acquisitions, and analyst optimism. However, the stock trades at a premium valuation with a P/E of 73.15, and near-term risks include margin pressures in China and rich valuation limiting upside beyond consensus targets. Revenue stability but slight profit margin compression in 2026 warrants monitoring.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Founded by designer Ralph Lauren in 1967, Ralph Lauren Corp. designs, markets, and distributes lifestyle products in North America, Europe, and Asia. Its products include apparel, footwear, eyewear, jewelry, leather goods, home products, and fragrances. The company's brands include Ralph Lauren Collection, Polo Ralph Lauren, Lauren Ralph Lauren, and Double RL. Distribution channels for Ralph Lauren include wholesale (including department stores and specialty stores), retail (including company-owned retail stores and e-commerce), and licensing.
Read more on RL →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →